Trials / Completed
CompletedNCT05745363
Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of AL2846 Capsule in Iodine-resistant Differentiated Thyroid Cancer With Previous TKI Treatment Failure
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects. The trial is a single-arm, multi-center, open label clinical study. Objective response rate (ORR) is the primary endpoint.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL2846 capsule | AL2846 is a multi-target tyrosine kinase inhibitor |
Timeline
- Start date
- 2023-02-24
- Primary completion
- 2025-11-13
- Completion
- 2025-11-13
- First posted
- 2023-02-27
- Last updated
- 2025-12-16
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05745363. Inclusion in this directory is not an endorsement.